{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:23:09Z","timestamp":1740126189020,"version":"3.37.3"},"reference-count":18,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370661"],"award-info":[{"award-number":["81370661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Recombinant human endostatin (rh<jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content>) can inhibit multiple myeloma, while its clinical efficacy in treating relapsed refractory multiple myeloma (<jats:styled-content style=\"fixed-case\">RRMM<\/jats:styled-content>) has not been assessed. One hundred and eleven <jats:styled-content style=\"fixed-case\">RRMM<\/jats:styled-content> patients were treated with four different regimens: combination of <jats:styled-content style=\"fixed-case\">VD<\/jats:styled-content> (velcade+dexamethasone) and rh<jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content> (n\u00a0=\u00a025), Thalidomide (Tha) and <jats:styled-content style=\"fixed-case\">VD<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content>, n\u00a0=\u00a022) combination, rh<jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content> and conventional chemotherapy combination (n\u00a0=\u00a032), and combination of conventional chemotherapy and Tha (n\u00a0=\u00a032). Significant differences were found in progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) between rh<jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content> combination groups and conventional chemotherapy combination groups. No statistical difference was found in overall response rate, overall survival or incidences of adverse effects. The combination of rh<jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">VD<\/jats:styled-content> or conventional chemotherapy is active in patients with <jats:styled-content style=\"fixed-case\">RRMM<\/jats:styled-content> and prolongs the <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> to improve the quality of life.<\/jats:p>","DOI":"10.1111\/1440-1681.13016","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T05:49:09Z","timestamp":1533620949000},"page":"1325-1327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma"],"prefix":"10.1111","volume":"45","author":[{"given":"Hao","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan\u2010de","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010zhang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2010na","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing\u2010lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng\u2010kuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong\u2010ping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-3660","authenticated-orcid":false,"given":"Bai\u2010jun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer hospital of Henan province  The Affiliated Cancer Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"e_1_2_1_5_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009576"},{"key":"e_1_2_1_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000466597.15540.54"},{"key":"e_1_2_1_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_1_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_1_5_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353312"},{"key":"e_1_2_1_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0919-z"},{"key":"e_1_2_1_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1129-7"},{"issue":"7","key":"e_1_2_1_5_9_1","first-page":"461","article-title":"Preliminary study on the anti\u2010leukemia effect of recombinant human endostatin","volume":"31","author":"Feng R","year":"2010","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"e_1_2_1_5_10_1","first-page":"642","article-title":"Antimyeloma effect of recombinant human endostatin in vitro","volume":"18","author":"Feng R","year":"2010","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_2_1_5_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_1_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0489"},{"key":"e_1_2_1_5_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0836"},{"key":"e_1_2_1_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0441-2"},{"key":"e_1_2_1_5_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1458"},{"key":"e_1_2_1_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2005.00009.x"},{"issue":"10","key":"e_1_2_1_5_17_1","first-page":"670","article-title":"Recombinant human endostatin in the treatment of advanced lung squamous cell carcinoma","volume":"19","author":"Xing P","year":"2016","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"e_1_2_1_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0770-6"},{"key":"e_1_2_1_5_19_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.9.4037"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.13016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.13016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T07:39:33Z","timestamp":1694763573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.13016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/1440-1681.13016"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.13016","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"type":"print","value":"0305-1870"},{"type":"electronic","value":"1440-1681"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"2017-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}